Trials / Recruiting
RecruitingNCT05236114
GEMINI-NSCLC: NSCLC Biomarker Study
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,200 (estimated)
- Sponsor
- Tempus AI · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observation | No intervention |
Timeline
- Start date
- 2022-06-22
- Primary completion
- 2029-06-01
- Completion
- 2029-06-01
- First posted
- 2022-02-11
- Last updated
- 2026-02-05
Locations
58 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05236114. Inclusion in this directory is not an endorsement.